Last update 23 Jan 2025

Wyeth AB

Subsidiary Company|
Sweden
|
www.wyeth.se

Overview

Tags

Other Diseases
Small molecule drug

Disease domain score
A glimpse into the focused therapeutic areas
no Data
No Data
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
no Data
No Data
Top 5 Drug TypeCount
Small molecule drug1

Related

125
Drugs associated with Wyeth AB
Moxidectin
Target
GluCls
Mechanism
Glutamate-gated chloride channel modulators
Active Org.
Medicines Development for Global Health LtdMedicines Development for Global Health Ltd
Originator Org.
Pfizer Inc.Pfizer Inc.
Active Indication
Onchocerciasis [+5]
Inactive Indication
Onchocerciasis, Ocular
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
US
First Approval Date13 Jun 2018
Inotuzumab Ozogamicin
Target
CD22 x DNA
Mechanism
CD22 inhibitors [+1]
Active Org.
Pfizer Inc.Pfizer Inc. [+4]
Originator Org.
Pfizer Inc.Pfizer Inc.
Active Indication
Philadelphia chromosome positive adult precursor acute lymphoblastic leukemia [+10]
Inactive Indication
Aggressive Non-Hodgkin Lymphoma [+10]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
EU [+3]
First Approval Date28 Jun 2017
Desvenlafaxine Fumarate
Target
NET x SERT
Mechanism
NET inhibitors [+1]
Active Org.
Apotex, Inc.Apotex, Inc.
Originator Org.
Teva Pharmaceuticals USA, Inc.
Active Indication
Depressive Disorder, Major
Inactive Indication-
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
US
First Approval Date11 Oct 2013
627
Clinical Trials associated with Wyeth AB
NCT04229264
/ Unknown statusPhase 3IIT
Efficacy and Safety of Apixaban in Reducing Restenosis and Limb Loss in Subjects With Symptomatic Peripheral Artery Disease (PAD) Undergoing Infrapopliteal Endovascular Peripheral Revascularization Procedures in Patients With Critical Limb
NCT01680250
/ Unknown statusPhase 2/3IIT
An Open-label, Prospective Clinical Trial to Evaluate the Effectiveness and Safety of Sirolimus to Reduce Cyst Growth in ADPKD Patients With Massive Polycystic Liver
NCT00911573
/ WithdrawnPhase 3
A Phase 3, Multicenter, Randomized, Double-Blind Study To Evaluate The Safety And Efficacy Of Tigecycline Versus Comparator (Clindamycin Or Vancomycin) For The Treatment Of Complicated Skin And Skin Structure Infections, Including Those Due To MRSA, In Pediatric Subject Ages 8 To 17 Years Old
100 Clinical Results associated with Wyeth AB
Login to view more data
0 Patents (Medical) associated with Wyeth AB
Login to view more data
100 Deals associated with Wyeth AB
Login to view more data
100 Translational Medicine associated with Wyeth AB
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 27 Jan 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Approved
1
124
Other
Login to view more data

Current Projects

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free